DaVita price target raised to $135 from $130 at Truist

Truist raised the firm’s price target on DaVita to $135 from $130 but keeps a Hold rating on the shares. The firm is adjusting its model after the company’s Q4 earnings beat and above-consensus guidance. Truist adds however that while it still likes the core dialysis business and the potential opportunity tied to integrated care longer term, it sees the near-term fundamentals on the stock as mixed given that the company’s improved capital efficiency is somewhat offset by industry pressures and slower organic volume trends.